News
GlobeImmune Receives Three Grants Under Federal Therapeutic Discovery Project Program
News
GlobeImmune Receives Three Grants Under Federal Therapeutic Discovery Project Program
Read time:
Want a FREE PDF version of This News Story?
Complete the form below and we will email you a PDF version of "GlobeImmune Receives Three Grants Under Federal Therapeutic Discovery Project Program"
First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?
Grant money will be received for each of the following clinical-stage therapeutic vaccine development programs:
• GI-5005, GlobeImmune's most advanced product candidate, is a therapeutic vaccine for the treatment of chronic hepatitis C virus (HCV) infection. Phase 2b clinical trials have demonstrated that when added to standard of care (SOC, pegylated interferon-alfa2a and ribavirin), GI-5005 improves sustained virologic response (SVR, or "cure") by 10% in treatment-naïve patients and 12% in prior non-responders compared to patients receiving SOC alone. Additionally, GI-5005 has been shown to increase SVR by 60% in patients with the IL28B T/T genotype, a patient group with the highest rate of treatment failure on SOC.
• GI-4000 targets cancers caused by mutations in the Ras oncogene product. The GI-4000 therapeutic vaccine is currently in Phase 2b clinical trials in patients with pancreas cancer, non-small cell lung cancer and colorectal cancer.
• GI-6207 is for the treatment of cancers that over-express carcinoembryonic antigen (CEA). This therapeutic vaccine is currently being evaluated in a Phase 1 clinical trial in patients with non-small cell lung cancer.
• GI-5005, GlobeImmune's most advanced product candidate, is a therapeutic vaccine for the treatment of chronic hepatitis C virus (HCV) infection. Phase 2b clinical trials have demonstrated that when added to standard of care (SOC, pegylated interferon-alfa2a and ribavirin), GI-5005 improves sustained virologic response (SVR, or "cure") by 10% in treatment-naïve patients and 12% in prior non-responders compared to patients receiving SOC alone. Additionally, GI-5005 has been shown to increase SVR by 60% in patients with the IL28B T/T genotype, a patient group with the highest rate of treatment failure on SOC.
• GI-4000 targets cancers caused by mutations in the Ras oncogene product. The GI-4000 therapeutic vaccine is currently in Phase 2b clinical trials in patients with pancreas cancer, non-small cell lung cancer and colorectal cancer.
• GI-6207 is for the treatment of cancers that over-express carcinoembryonic antigen (CEA). This therapeutic vaccine is currently being evaluated in a Phase 1 clinical trial in patients with non-small cell lung cancer.
Advertisement
